Date:11/1/2011

first-generation TAXUS® Express® Paclitaxel-Eluting Coronary Stent System in more than 1,200 patients with de novo lesions.  The PERSEUS Small Vessel trial compares the performance of the ION Stent in 223 patients with small vessels to a matched historical control group of 125 patients treated with the Express® bare-metal stent.  Results will be presented from 8 to 10 a.m. during a poster session in Hall D.  The Company plans to issue a press release announcing trial results during this time.

Comparison of PERSEUS/ATLAS Two-Year Trial Data.  Dean Kereiakes, M.D., will present an analysis of case-matched data from 2,298 patients enrolled in the PERSEUS and TAXUS ATLAS clinical trials.  The study will compare two-year clinical outcomes of the ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System (TAXUS Element) to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System.  Both stents use the same drug and polymer but differ in metal alloy composition, stent design and strut thickness.  Results will be presented from 8 to 10 a.m. during a poster session in Hall D.  The Company plans to issue a press release announcing trial results during this time.

PLATINUM Long Lesion Primary Endpoint Data.  Paul S. Teirstein, M.D., will present 12-month primary endpoint data from the PLATINUM Long Lesion trial, which compares outcomes with the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System to a pre-defined performance goal based on historical results with the 32-mm TAXUS® Express2™ Paclitaxel-Eluting Coronary Stent System in patients with long lesions.  Results will be presented from 8 to 10 a.m. during a poster session in Hall D.  The Company plans to issue a press release announcing trial results during this time.

TAXUS Liberte Post-Approval Study.  David Lee, M.D.,
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death